vs
Side-by-side financial comparison of KKR Real Estate Finance Trust Inc. (KREF) and Strata Critical Medical, Inc. (SRTA). Click either name above to swap in a different company.
KKR Real Estate Finance Trust Inc. is the larger business by last-quarter revenue ($25.8M vs $22.7M, roughly 1.1× Strata Critical Medical, Inc.). On growth, Strata Critical Medical, Inc. posted the faster year-over-year revenue change (361.2% vs -26.6%). Over the past eight quarters, KKR Real Estate Finance Trust Inc.'s revenue compounded faster (-18.8% CAGR vs -33.6%).
KKR Real Estate Finance Trust Inc. is a specialized real estate finance firm sponsored by global investment firm KKR. It primarily originates, acquires, and manages a portfolio of senior secured commercial real estate loans, mostly backed by high-quality institutional commercial properties across the United States, delivering stable risk-adjusted returns to investors via interest income from its diversified assets.
Strata Critical Medical, Inc. is a medical technology firm designing, producing and distributing disposable medical products for critical care, anesthesia and surgical use cases. It serves healthcare providers across North America and some European markets, focusing on improving patient safety and clinical efficiency.
KREF vs SRTA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.8M | $22.7M |
| Net Profit | $-26.2M | — |
| Gross Margin | — | -0.9% |
| Operating Margin | -105.1% | -18.4% |
| Net Margin | -101.7% | — |
| Revenue YoY | -26.6% | 361.2% |
| Net Profit YoY | -229.6% | — |
| EPS (diluted) | $-0.49 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.8M | $22.7M | ||
| Q3 25 | $25.3M | $49.3M | ||
| Q2 25 | $30.2M | $70.8M | ||
| Q1 25 | $31.3M | $54.3M | ||
| Q4 24 | $35.1M | $-8.7M | ||
| Q3 24 | $37.0M | $36.1M | ||
| Q2 24 | $40.4M | $67.9M | ||
| Q1 24 | $39.1M | $51.5M |
| Q4 25 | $-26.2M | — | ||
| Q3 25 | $13.8M | $57.4M | ||
| Q2 25 | $-29.7M | $-3.7M | ||
| Q1 25 | $-4.9M | $-3.5M | ||
| Q4 24 | $20.3M | — | ||
| Q3 24 | $-7.4M | $-2.0M | ||
| Q2 24 | $25.8M | $-11.3M | ||
| Q1 24 | $-3.1M | $-4.2M |
| Q4 25 | — | -0.9% | ||
| Q3 25 | — | 23.6% | ||
| Q2 25 | — | 25.1% | ||
| Q1 25 | — | 22.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 20.8% | ||
| Q2 24 | — | 24.1% | ||
| Q1 24 | — | 19.7% |
| Q4 25 | -105.1% | -18.4% | ||
| Q3 25 | 50.4% | -11.4% | ||
| Q2 25 | -101.3% | -7.0% | ||
| Q1 25 | -18.3% | -14.0% | ||
| Q4 24 | 55.8% | — | ||
| Q3 24 | -19.6% | -19.7% | ||
| Q2 24 | 63.3% | -17.9% | ||
| Q1 24 | -8.7% | -19.2% |
| Q4 25 | -101.7% | — | ||
| Q3 25 | 54.4% | 116.5% | ||
| Q2 25 | -98.5% | -5.3% | ||
| Q1 25 | -15.5% | -6.4% | ||
| Q4 24 | 57.7% | — | ||
| Q3 24 | -20.0% | -5.4% | ||
| Q2 24 | 63.9% | -16.7% | ||
| Q1 24 | -7.9% | -8.2% |
| Q4 25 | $-0.49 | $-0.11 | ||
| Q3 25 | $0.12 | $0.70 | ||
| Q2 25 | $-0.53 | $-0.05 | ||
| Q1 25 | $-0.15 | $-0.04 | ||
| Q4 24 | $0.22 | $-0.11 | ||
| Q3 24 | $-0.19 | $-0.03 | ||
| Q2 24 | $0.29 | $-0.15 | ||
| Q1 24 | $-0.13 | $-0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $84.6M | $31.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $279.1M |
| Total Assets | $6.5B | $325.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $84.6M | $31.0M | ||
| Q3 25 | $204.1M | $22.8M | ||
| Q2 25 | $107.7M | $58.8M | ||
| Q1 25 | $106.4M | $34.8M | ||
| Q4 24 | $104.9M | $18.4M | ||
| Q3 24 | $108.8M | $20.0M | ||
| Q2 24 | $107.2M | $26.3M | ||
| Q1 24 | $106.5M | $36.8M |
| Q4 25 | $1.2B | $279.1M | ||
| Q3 25 | $1.2B | $283.0M | ||
| Q2 25 | $1.2B | $223.1M | ||
| Q1 25 | $1.3B | $219.7M | ||
| Q4 24 | $1.3B | $221.9M | ||
| Q3 24 | $1.4B | $233.5M | ||
| Q2 24 | $1.4B | $229.4M | ||
| Q1 24 | $1.4B | $236.6M |
| Q4 25 | $6.5B | $325.5M | ||
| Q3 25 | $6.5B | $335.1M | ||
| Q2 25 | $6.8B | $257.9M | ||
| Q1 25 | $6.6B | $250.6M | ||
| Q4 24 | $6.4B | $256.7M | ||
| Q3 24 | $6.8B | $282.9M | ||
| Q2 24 | $7.1B | $280.3M | ||
| Q1 24 | $7.3B | $282.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $72.3M | $-8.3M |
| Free Cash FlowOCF − Capex | — | $-10.2M |
| FCF MarginFCF / Revenue | — | -44.7% |
| Capex IntensityCapex / Revenue | — | 8.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-58.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $72.3M | $-8.3M | ||
| Q3 25 | $18.5M | $-37.3M | ||
| Q2 25 | $21.1M | $-3.1M | ||
| Q1 25 | $15.9M | $-246.0K | ||
| Q4 24 | $132.6M | $-1.8M | ||
| Q3 24 | $49.1M | $6.4M | ||
| Q2 24 | $30.6M | $8.4M | ||
| Q1 24 | $34.5M | $-15.6M |
| Q4 25 | — | $-10.2M | ||
| Q3 25 | — | $-40.1M | ||
| Q2 25 | — | $-5.4M | ||
| Q1 25 | — | $-2.9M | ||
| Q4 24 | — | $-6.3M | ||
| Q3 24 | — | $-3.0M | ||
| Q2 24 | — | $-7.7M | ||
| Q1 24 | — | $-16.4M |
| Q4 25 | — | -44.7% | ||
| Q3 25 | — | -81.4% | ||
| Q2 25 | — | -7.6% | ||
| Q1 25 | — | -5.3% | ||
| Q4 24 | — | 72.7% | ||
| Q3 24 | — | -8.2% | ||
| Q2 24 | — | -11.4% | ||
| Q1 24 | — | -31.8% |
| Q4 25 | — | 8.1% | ||
| Q3 25 | — | 5.7% | ||
| Q2 25 | — | 3.2% | ||
| Q1 25 | — | 4.8% | ||
| Q4 24 | — | -52.6% | ||
| Q3 24 | — | 25.8% | ||
| Q2 24 | — | 23.8% | ||
| Q1 24 | — | 1.6% |
| Q4 25 | — | — | ||
| Q3 25 | 1.34× | -0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.54× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.19× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KREF
Segment breakdown not available.
SRTA
| Other Clinical | $11.4M | 50% |
| Transplant Clinical | $9.0M | 39% |
| Other | $2.4M | 11% |
